Mayne Pharma announces change of auditor
Released
Released
Announcement PDF
ASX Announcement
MAYNE PHARMA ANNOUNCES CHANGE OF AUDITOR
30 November 2023, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX) (Mayne Pharma
or the Company) announces that, following shareholder approval obtained at the Annual General
Meeting held today, BDO Audit Pty Ltd (BDO) has been appointed as the auditor of the Company
with effect from today, 30 November 2023.
The appointment of BDO follows receipt of resignation from Ernst & Young by the Company and
the Australian Securities and Investments Commission's consent to the resignation in accordance
with section 329(5) of the Corporations Act 2001 (Cth).
The reason for the change in auditor was to give effect to the result of a competitive audit tender
process conducted during 2023.
For further information contact:
Australia:
Craig Haskins
+61 421 029 843
ir@maynepharma.com
US:
Lisa M. Wilson
+1 917-543-9932
ir@maynepharma.com
Authorised for release to the ASX by the Board
About Mayne Pharma
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel
pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma also
provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40year track record of innovation and success in developing new oral drug delivery systems. These
technologies have been successfully commercialised in numerous products that continue to be marketed
around the world. To learn more about Mayne Pharma, please visit maynepharma.com.
Share your feedback
Discover